Unravelling the Role of Glycogen Synthase Kinase-3 in Alzheimer’s Disease-Related Epileptic Seizures
Alzheimer’s disease (AD) is the most common form of dementia. An increasing body of evidence describes an elevated incidence of epilepsy in patients with AD, and many transgenic animal models of AD also exhibit seizures and susceptibility to epilepsy. However, the biological mechanisms that underlie...
Main Authors: | Runxuan Lin, Nigel Charles Jones, Patrick Kwan |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/10/3676 |
Similar Items
-
Crosstalk between Cdk5 and GSK3β: Implications for Alzheimer's Disease
by: Olivia Engmann, et al.
Published: (2009-05-01) -
Glycogen synthase kinase 3 (GSK-3) and its inhibitors : drug discovery and development /
by: Martinez, Ana, 1961-, et al.
Published: (2006) -
Targeting hyperphosphorylated tau with sodium selenate suppresses seizures in rodent models
by: Nigel C. Jones, et al.
Published: (2012-03-01) -
Human tau accumulation promotes glycogen synthase kinase-3β acetylation and thus upregulates the kinase: A vicious cycle in Alzheimer neurodegeneration
by: Qiuzhi Zhou, et al.
Published: (2022-04-01) -
Epileptic Seizures or not, that is the question: a case report
by: B. Wildenberg, et al.
Published: (2022-06-01)